Ticker LaunchCanada to US · Cross-listing · NGEN
Nervgen Pharma Corp.
Nervgen Pharma Corp. (NGEN), a British Columbia-based company, cross-listed on Nasdaq on Jan 7, 2026, registering its securities on Form 8-A12B.
NervGen Pharma Corp. is a clinical-stage biopharmaceutical company developing neuroreparative therapeutics intended to help the nervous system repair itself. Its initial focus is spinal cord injury, and its lead drug candidate is NVG-291.
- Type
- Cross-listing
- US exchange
- Nasdaq
- Ticker
- NGEN
- Listed
- Jan 7, 2026
- Province
- British Columbia
- Registration form
- 8-A12B
- Security
- Common shares
- Sector
- Biotech & pharma
More on this listing for subscribers
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration (8-A12B) Jan 7, 2026
- All filings on EDGAR CIK 1751912
Other Canadian companies listing in the US
- Satellos Bioscience Inc.Nasdaq · Feb 5, 2026
- Quantum eMotion Corp.NYSE American · Jan 22, 2026
- Mayfair Gold Corp.NYSE American · Jan 20, 2026
- Blue Moon Metals Inc.Nasdaq · Jan 16, 2026
- Santacruz Silver Mining Ltd.Nasdaq · Jan 12, 2026
- F3 Uranium Corp.Nasdaq · Dec 12, 2025